CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/8/e003100.full |
| _version_ | 1818735960758681600 |
|---|---|
| author | Wei Huang Qiang Xu Yi Wang Yang Sun Zhigang Tian Hongqi Chen Xiaofan Sun Binglin Wang Guoliang Deng Xingxin Wu Yanghong Gu Zhimin Fan |
| author_facet | Wei Huang Qiang Xu Yi Wang Yang Sun Zhigang Tian Hongqi Chen Xiaofan Sun Binglin Wang Guoliang Deng Xingxin Wu Yanghong Gu Zhimin Fan |
| author_sort | Wei Huang |
| collection | DOAJ |
| first_indexed | 2024-12-18T00:29:34Z |
| format | Article |
| id | doaj.art-8e475ffef11c4ac19294e49e7949452a |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-18T00:29:34Z |
| publishDate | 2021-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-8e475ffef11c4ac19294e49e7949452a2022-12-21T21:27:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-08-019810.1136/jitc-2021-003100CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cellWei Huang0Qiang Xu1Yi Wang2Yang Sun3Zhigang Tian4Hongqi Chen5Xiaofan Sun6Binglin Wang7Guoliang Deng8Xingxin Wu9Yanghong Gu10Zhimin Fan11State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Proctology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaSchool of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDepartment of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People`s Hospital, Shanghai, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, ChinaDepartment of Proctology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, Chinahttps://jitc.bmj.com/content/9/8/e003100.full |
| spellingShingle | Wei Huang Qiang Xu Yi Wang Yang Sun Zhigang Tian Hongqi Chen Xiaofan Sun Binglin Wang Guoliang Deng Xingxin Wu Yanghong Gu Zhimin Fan CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell Journal for ImmunoTherapy of Cancer |
| title | CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
| title_full | CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
| title_fullStr | CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
| title_full_unstemmed | CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
| title_short | CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
| title_sort | cxcr6 is required for antitumor efficacy of intratumoral cd8 t cell |
| url | https://jitc.bmj.com/content/9/8/e003100.full |
| work_keys_str_mv | AT weihuang cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT qiangxu cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT yiwang cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT yangsun cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT zhigangtian cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT hongqichen cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT xiaofansun cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT binglinwang cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT guoliangdeng cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT xingxinwu cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT yanghonggu cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell AT zhiminfan cxcr6isrequiredforantitumorefficacyofintratumoralcd8tcell |